期刊文献+

维生素C联合碳酸氢钠对早期糖尿病肾病患者经皮冠状动脉介入治疗时造影剂肾病的预防效果 被引量:2

Effect of Vitamin C Combined with Sodium Bicarbonate on the Prevention of PCI Contrast Agent Nephropathy in Patients with Early Diabetic Nephropathy
下载PDF
导出
摘要 目的分析维生素C联合碳酸氢钠对早期糖尿病肾病患者经皮冠状动脉介入治疗(PCI)时造影剂肾病的预防效果。方法选取2017年5月至2019年7月在厦门大学附属第一医院行PCI的82例早期糖尿病肾病患者,根据治疗方式的不同分为两组,各41例。对照组采用常规水化法,试验组在对照组基础上采用维生素C联合碳酸氢钠治疗,比较两组造影前后的肌酐清除率(CCr)、血尿素氮(BUN)和血清肌酐(SCr)水平及造影剂肾病发生情况。结果造影后3 d,试验组CCr高于对照组,BUN和SCr水平低于对照组,差异均有统计学意义(P<0.05);试验组造影剂肾病发生率低于对照组,差异有统计学意义(P<0.05)。结论维生素C联合碳酸氢钠对早期糖尿病肾病患者PCI时造影剂肾病的预防效果较好。 Objective To analyze the preventive effect of vitamin C combined with sodium bicarbonate on PCI contrast agent nephropathy in patients with early diabetic nephropathy.Methods A total of 82 patients with early diabetic nephropathy who underwent PCI in the First Affiliated Hospital of Xiamen University from May 2017 to July 2019 were selected,and divided into two groups according to the different methods of treatment,41 cases each.The control group using conventional hydration,on this basis,the experimental group was treated with vitamin C in combination with sodium bicarbonate,compared the two groups before and after angiography in patients with creatinine clearance rate(CCr),blood urea nitrogen(BUN)and serum creatinine(SCr)levels,as well as the contrast nephropathy is happening.Results Three days after angiography,the level of CCr in the control group was lower than that in the experimental group(P<0.05),and the level of BUN and SCr in the control group were higher than that in the experimental group(P<0.05).The incidence of contrast nephropathy in the control group was higher than that in the experimental group(P<0.05).Conclusion The application of vitamin C combined with sodium bicarbonate hydration in PCI in early diabetic nephropathy can effectively prevent contrast agent nephropathy.
作者 郭南京 易志刚 赖杨贤 李津 Guo Nanjing;Yi Zhigang;Lai Yangxian;Li Jin(Department of Cadre Sanitarian, the First Affiliated Hospital of Xiamen University, Xiamen Fujian 361100, China)
出处 《医疗装备》 2021年第4期7-8,21,共3页 Medical Equipment
关键词 糖尿病肾病 经皮冠状动脉介入治疗 造影剂肾病 碳酸氢钠 维生素C 预防效果 Diabetic nephropathy PCI Contrast nephropathy Sodium bicarbonate Vitamin C Protective effect
  • 相关文献

参考文献14

二级参考文献101

  • 1李文华,韩飞,李东野,徐通达,张延斌,朱红.前列地尔脂微球载体制剂对急性冠状动脉综合征患者介入治疗术后造影剂肾病的预防作用[J].中华临床医师杂志(电子版),2011,5(14):4228-4230. 被引量:12
  • 2KDOKI.KDOQI Clinical Prac'tice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease[J].Am J Kidney Dis,2007,49 (Suppl 2):S12-154.
  • 3Rodbard HW,Blonde L,Braithwaite SS,et al.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus[J].Endocr Pract,2007,13(Suppl 1):1 -68.
  • 4Mancia G,De Backer G,Dominiczak A,et al.2007 Guidelines for the management of arterial hypertension:The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)[J].Eur Heart J,2007,28 (12):1462-1536.
  • 5Rodby RA,Rohde RD,Clarke WR,et al.The Irbesartan type Ⅱ diabetic nephropathy trial:study design and baseline patient charactoristics.For the Collaborative Study Group[J].Nephrol Dial Transplant,2000,15:487-497.
  • 6Brenner BM,Cooper ME,de Zeenw D,et al.Effects of Inesrtan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy[J].N Engl J Med,20010345:861-869.
  • 7Viberti G,Whecldon NM.Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:a blood pressure-independent effect[J].Circulation,2002,106:672-678.
  • 8Rossing K,Christensen PK,Andersen S,et al.Comparative effects of lrbosartan on ambulatory and office blood pressure:a substudy of ambulatory blood pressure from the lrbesartan in Patients with Type 2 Diabetes and Micreslbuminuria study[J].Diabetes Care,2003,26:569-574.
  • 9Diercks GF,Janssen WM,van Boven AJ,et al.Rationale,design,and baseline characteristics of a trial of prevention of cardiovascular and renal disease with fosinopril and pravastatin in nonhypertensive,nonhypercholesterolemic subjects with microalbuminuria(the Prevention of REnal and Vascular ENdstage Disease Intervention Trial[PREVEND IT])[J].Am J Cardiol,2000,86:635-638.
  • 10Ansquer JC,Fouchor C,Rattier S,et al.Fenofibrate reduces progresaion to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes:results from the Diabetes Atherosclerosis Intervention Study (DAIS).[J] Am J Kidney Dis,2005,45:485-493.

共引文献173

同被引文献29

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部